Glucose‐lowering medicines use before and after entry into long‐term care facilities
GLM use peaked in the first 3 months following LTCF entry, driven mainly by insulin, hence, residents may benefit from close monitoring of diabetes treatment during this period.
Authors
- Gillian E. Caughey (ORCID: https://orcid.org/0000-0003-1192-4121)
- Catherine Lang (ORCID: https://orcid.org/0000-0003-4828-5749)
- Janet K. Sluggett (ORCID: https://orcid.org/0000-0002-9059-5209)
- Maria C. Inacio (ORCID: https://orcid.org/0000-0001-8261-2665)
- Tracy Air (ORCID: https://orcid.org/0000-0002-4834-4238)
- Y. Wondimkun (ORCID: https://orcid.org/0000-0002-2869-7917)
Institutions
- University of South Australia (AU)
- Hawassa University (ET)
- South Australian Health and Medical Research Institute (AU)
Publication Details
- Journal
- Diabetes Obesity and Metabolism
- Published
- 2024-09-02
- DOI
- https://doi.org/10.1111/dom.15905
- Citations
- 3
- Primary Topic
- Pharmaceutical Practices and Patient Outcomes
- Type
- article
- Field-Weighted Citation Impact
- 1.03
Funders
- South Australian Health and Medical Research Institute
- Queensland Health
- Government of South Australia
- Australian Government
- University of South Australia
- Department of Health, State Government of Victoria
- NSW Ministry of Health
- Department for Innovation and Skills, Government of South Australia
- Medical Research Council
- National Health and Medical Research Council